Literature DB >> 26550300

Clinical value of microRNA-23a upregulation in non-small cell lung cancer.

Wei-Qing Qu1, Lei Liu1, Zhe Yu1.   

Abstract

BACKGROUND: MiR-23a function as an oncogene in several human cancers, however, its clinical value has not been investigated in NSCLC.
METHODS: Tissue samples were obtained from 127 NSCLC patients who underwent complete resection at Yantaishan Hospital from March 2008 to January 2014. The expression level of miR-23a was detected in NSCLC tissues and the matched adjacent lung tissues by qRT-PCR. The survival analysis was estimated by the Kaplan-Meier method and was compared by using the log-rank test. Multivariate analysis was performed using the Cox proportional hazard model.
RESULTS: The expression level of miR-23a was significantly up-regulated in NSCLC tissues compared with matched adjacent lung tissues (P<0.001). The expression of miR-23a in NSCLC tissues was significantly associated with the smoking status (P=0.001), tumor size (P=0.002), lymphnode metastasis (P<0.001), TNM stage (P=0.001), and tumor differentiation (P=0.004). The overall survival was significantly lower in patients with higher miR-23a expression than in patients with lower miR-23a expression (P=0.02). In addition, multivariate analysis demonstrated that high miR-23a expression (HR=3.558, 95% CI: 2.982-6.635, P=0.011) was significant prognostic factor for NSCLC patients.
CONCLUSIONS: miR-23a might play an oncogenic role in NSCLC and is a poor prognostic factor. Our results must be verified by large-scale prospective studies with standardized methodology.

Entities:  

Keywords:  MicroRNA-23a; NSCLC; biomarker; expression; prognosis

Year:  2015        PMID: 26550300      PMCID: PMC4612985     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer.

Authors:  Tian Yang; Asmitananda Thakur; Tianjun Chen; Li Yang; Gao Lei; Yiqian Liang; Shuo Zhang; Hui Ren; Mingwei Chen
Journal:  Tumour Biol       Date:  2015-01-22

Review 2.  Update in lung cancer and mesothelioma 2012.

Authors:  Charles A Powell; Balazs Halmos; Serge P Nana-Sinkam
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

3.  A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer.

Authors:  Boone Goodgame; Avinash Viswanathan; C Ryan Miller; Feng Gao; Bryan Meyers; Richard J Battafarano; Alexander Patterson; Joel Cooper; Tracey J Guthrie; Jeffrey Bradley; Giancarlo Pillot; Ramaswamy Govindan
Journal:  Am J Clin Oncol       Date:  2008-02       Impact factor: 2.339

4.  Correlation between miR-23a and onset of hepatocellular carcinoma.

Authors:  Lidao Bao; Jianfen Zhao; Xiaoxia Dai; Yi Wang; Ruilian Ma; Yila Su; Hongwei Cui; Jianxiang Niu; Shiming Bai; Zhiying Xiao; Hongwei Yuan; Zhou Yang; Changqing Li; Rui Cheng; Xianhua Ren
Journal:  Clin Res Hepatol Gastroenterol       Date:  2014-01-10       Impact factor: 2.947

5.  Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression.

Authors:  Iris Barshack; Eti Meiri; Shai Rosenwald; Danit Lebanony; Meital Bronfeld; Sarit Aviel-Ronen; Kinneret Rosenblatt; Sylvie Polak-Charcon; Ilit Leizerman; Meital Ezagouri; Merav Zepeniuk; Norberto Shabes; Lahav Cohen; Sarit Tabak; Dalia Cohen; Zvi Bentwich; Nitzan Rosenfeld
Journal:  Int J Biochem Cell Biol       Date:  2009-03-06       Impact factor: 5.085

6.  MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor.

Authors:  Li-Hua Zhu; Tao Liu; Hua Tang; Rui-Qing Tian; Chang Su; Min Liu; Xin Li
Journal:  FEBS J       Date:  2010-08-05       Impact factor: 5.542

7.  MiR-23a functions as a tumor suppressor in osteosarcoma.

Authors:  Yu He; Chunqing Meng; Zengwu Shao; Hong Wang; Shuhua Yang
Journal:  Cell Physiol Biochem       Date:  2014-10-08

Review 8.  Management of non-small-cell lung cancer: recent developments.

Authors:  Martin Reck; David F Heigener; Tony Mok; Jean-Charles Soria; Klaus F Rabe
Journal:  Lancet       Date:  2013-08-24       Impact factor: 79.321

9.  Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation.

Authors:  Signe Søes; Iben Lyster Daugaard; Brita Singers Sørensen; Andreas Carus; Manuel Mattheisen; Jan Alsner; Jens Overgaard; Henrik Hager; Lise Lotte Hansen; Lasse Sommer Kristensen
Journal:  Oncoscience       Date:  2014-05-23

10.  Lung cancer biomarkers: State of the art.

Authors:  Sangeetha Subramaniam; Ram Krishna Thakur; Vinod Kumar Yadav; Ranjan Nanda; Shantanu Chowdhury; Anurag Agrawal
Journal:  J Carcinog       Date:  2013-02-28
View more
  11 in total

1.  [Plasma miRNA-23a and miRNA-451 as candidate biomarkers for early diagnosis of nonsmall cell lung cancer: a case-control study].

Authors:  Shengjin Cui; Zhaopeng Cao; Weiquan Guo; Huijun Yu; Rong Huang; Yunfeng Wu; Yiwen Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-06-30

2.  MicroRNA-23a/24-2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta-analysis.

Authors:  Jing Quan; Suyue Liu; Kangfu Dai; Lu Jin; Tao He; Xiang Pan; Yongqing Lai
Journal:  Mol Clin Oncol       Date:  2017-11-08

3.  Disease relevant modifications of the methylome and transcriptome by particulate matter (PM2.5) from biomass combustion.

Authors:  Katharina Heßelbach; Gwang-Jin Kim; Stephan Flemming; Thomas Häupl; Marc Bonin; Regina Dornhof; Stefan Günther; Irmgard Merfort; Matjaz Humar
Journal:  Epigenetics       Date:  2017-10-27       Impact factor: 4.528

4.  The Oncogenic Role of Tribbles 1 in Hepatocellular Carcinoma Is Mediated by a Feedback Loop Involving microRNA-23a and p53.

Authors:  Ying Ye; Guangdong Wang; Guoyu Wang; Juhua Zhuang; Saifei He; Yanan Song; Jing Ni; Wei Xia; Jiening Wang
Journal:  Front Physiol       Date:  2017-11-10       Impact factor: 4.566

5.  Long Noncoding RNA GAS5 Suppresses Tumorigenesis by Inhibiting miR-23a Expression in Non-Small Cell Lung Cancer.

Authors:  Yongcheng Mei; Jinchun Si; Yun Wang; Zhuangshi Huang; Haiwen Zhu; Shijun Feng; Xuezhi Wu; Liwen Wu
Journal:  Oncol Res       Date:  2017-01-05       Impact factor: 5.574

6.  The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer.

Authors:  Xiaoqing Fan; Shaolin Tao; Qing Li; Bo Deng; Qun-You Tan; Hua Jin
Journal:  Mol Ther Oncolytics       Date:  2021-12-23       Impact factor: 7.200

7.  Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.

Authors:  Stefan Hatzl; Olivia Geiger; Maja Kim Kuepper; Veronica Caraffini; Till Seime; Tobias Furlan; Erika Nussbaumer; Rotraud Wieser; Martin Pichler; Marcel Scheideler; Katarzyna Nowek; Mojca Jongen-Lavrencic; Franz Quehenberger; Albert Wölfler; Jakob Troppmair; Heinz Sill; Armin Zebisch
Journal:  Cancer Res       Date:  2016-04-15       Impact factor: 12.701

8.  Upregulated expression of miR-421 is associated with poor prognosis in non-small-cell lung cancer.

Authors:  Yunxia Li; Xiaomei Cui; Yongdeng Li; Tingting Zhang; Shuyun Li
Journal:  Cancer Manag Res       Date:  2018-08-13       Impact factor: 3.989

9.  Expression of miR-23a and miR-135 and tumor markers in gastric cancer patients and the significance in diagnosis.

Authors:  Likui Yin; Guangxiao Xu; Yuntao Zhu; Yongqiang Wang
Journal:  Oncol Lett       Date:  2019-10-01       Impact factor: 2.967

10.  Serum Extracellular Vesicle-Derived miRNAs in Patients with Non-Small Cell Lung Cancer-Search for Non-Invasive Diagnostic Biomarkers.

Authors:  Jolanta Kryczka; Monika Migdalska-Sęk; Jacek Kordiak; Justyna M Kiszałkiewicz; Dorota Pastuszak-Lewandoska; Adam Antczak; Ewa Brzeziańska-Lasota
Journal:  Diagnostics (Basel)       Date:  2021-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.